Most analysts predict the market for new weight reduction medication like Wegovy and Mounjaro will likely be monumental, however estimates differ for its actual dimension relying on who you ask.
On Monday, Citi raised its estimate for incretin drug sales to $71 billion by 2035, up from its prior estimate of $55 billion. That viewpoint appears actually conservative when positioned aspect by aspect with predictions like Guggenheim’s. Last month, the agency made a case for there being a $150 billion to $200 billion opportunity for these medication.
Guggenheim analyst Seamus Fernandez’s conviction comes from his perception that GLP-1-based incretins will grow to be the most prescription drugs ever by or earlier than 2031. Not solely do these medication work properly for managing insulin ranges and serving to sufferers drop some weight, research are underway to present their advantages for cardiovascular health, sleep apnea and persistent kidney illness to title a couple of.
Fernandez expects $50 billion in GLP-1 sales will come from sufferers with diabetes as incretin treatment turns into the customary of care for this situation. Patients with weight problems will add one other $140 billion in sales, he mentioned.
Citi’s forecast does replicate extra modest assumptions. It is assuming the variety of sufferers opting for the weekly injections will likely be beneath 10% of the non-Medicare overweight affected person inhabitants.
“Despite the apparent demand and unmet medical want, we proceed to battle with our lack of ability to predict with any accuracy the long-term upside for incretins given the >42% prevalence of weight problems,” analyst Andrew Baum, wrote in a analysis notice Monday.
The medication are very dear, with a listing value of as a lot as $1,350 per 30 days for Wegovy. At the second, non-public insurance coverage protection is not a assure for these in search of weight reduction therapy, and the federal Medicare program does not cowl weight reduction medication at all.
Still, the insurance coverage state of affairs is enhancing, as are provide bottlenecks.
Quite quite a lot of analysts count on these points will likely be labored out over time and count on peak sales for these medicines to reach around $100 billion by 2030. Goldman Sachs joined this camp final Monday with its newest forecast.
“In 2030, we estimate that ~15mn adults in the US will likely be handled with AOM [anti-obesity medication] for persistent weight administration (excluding sufferers handled for sort 2 diabetes), which represents ~13% penetration into the U.S. grownup inhabitants,” analyst Chris Shibutani wrote in a analysis notice.
Shibutani mentioned about $52 billion will likely be captured by Eli Lilly, which sells Mounjaro, or tirzepatide. Lilly expects the Food and Drug Administration to approve this drug to deal with weight problems by the finish of this 12 months. Its pipeline additionally consists of experimental, next-generation incretins orforglipron and retatrutide.
Eli Lilly shares have risen almost 60% since the begin of the 12 months.
Novo Nordisk, which is already accepted to promote Wegovy (semaglutide) as a weight reduction therapy, additionally has extra AOM medication in its pipeline equivalent to CagriSema.
Many business analysts anticipate that Novo Nordisk and Lilly will reign over this market section in a duopoly for fairly some time. There are another drugmakers trying to enter this section, however they continue to be considerably behind. Goldman’s mannequin forecasts the two firms could have an 80% share of the market in 2030.
Both shares are up considerably on the again of optimism for the anti-obesity drug market. Lilly shares have gained almost 60%, whereas Novo Nordisk has climbed greater than 40%.
Read extra in CNBC PRO: